electroCore develops non-invasive vagus nerve stimulation (nVNS) technology to provide safe and clinically validated treatments for patients suffering from chronic pain and related conditions. By utilizing nVNS, the company aims to enhance treatment options and improve the quality of life for individuals dissatisfied with existing therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals experience chronic pain and related conditions that are not adequately managed by existing therapies, leading to a diminished quality of life. Current treatment options may be limited in efficacy, have undesirable side effects, or be inaccessible to certain patient populations.
Solution
electroCore develops and commercializes non-invasive vagus nerve stimulation (nVNS) technology as a bioelectronic medicine approach to treat various disorders. Their proprietary technology delivers mild electrical pulses to the vagus nerve through the skin, modulating nerve activity and influencing relevant physiological pathways. This stimulation aims to provide therapeutic benefits for patients suffering from conditions where vagus nerve modulation can play a role. The company's products offer a non-pharmaceutical alternative or adjunct therapy for individuals seeking relief from their symptoms.
Target Audience
The primary target audience includes patients suffering from chronic pain and related conditions, as well as healthcare providers seeking alternative or adjunctive treatment options.
Features
- Non-invasive vagus nerve stimulation (nVNS) technology
- Proprietary stimulation waveform and delivery system
- Portable and handheld devices for convenient use
- Clinically validated for specific indications